Effect of Genetic Polymorphism on the Occurrence of Post-Operative Atrial Fibrillation After CABG

NCT03871647 | Completed DMC

• 1 other identifier: PhD 53
• Study Type: observational
• Target: 256
• Locations: 1 country
• Sites: 1

Brief Summary

Postoperative Atrial Fibrillation (POAF) is one of the most common complications following coronary artery bypass grafting (CABG) occurring to 20% - 40% of patients. It is associated with prolonged hospitalization, increased hospital costs, increased complications and mortality rate. Despite the use of Beta Blockers, approximately 20% of patients develop atrial fibrillation following CABG surgery, suggesting a role for polymorphism in the genes The aim of the present study is to determine the minor allele frequency of some of the genes that affect the beta blockers' response and to determine the association between polymorphism in these genes and the occurrence of postoperative atrial fibrillation after coronary artery bypass grafting in Egyptian patients receiving perioperative beta blockers.

Conditions

Coronary Bypass Graft Surgery; Atrial Fibrillation

Outcome Measures

Primary Outcomes (1)

• Occurrence of Atrial fibrillation

  Atrial fibrillation based on postoperative electrocardiogram. AF diagnostic criteria will include absence of discrete P waves, the RR intervals follow unrepetitive form and the ranges of ventricular rate usually between 90 and 170 beats/min.

  within 6 days after the operation

Study Arms (2)

POAF group

Patients who will experience AF at any time during the first six days after the operation.

Drug: Beta blocker

Non POAF group

Patients with a sinus rhythm during the first six days after the operation.

Drug: Beta blocker

Interventions

Beta blocker DRUG

perioperative beta blockers

Non POAF group; POAF group

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Egyptian patients undergoing Coronary Artery Bypass grafting Surgery

You may qualify if:

• Age above 18 years.
• Candidates for CABG surgery without a concurrent valve surgery.
• Patients receiving perioperative beta blockers before new onset of postoperative AF.

You may not qualify if:

• Patients who have either persistent or permanent AF, atrial flutter or atrial tachycardia on ECG obtained on the day of the operation.
• Serum creatinine \>2 mg/dL before the surgery.
• Uncontrolled thyroid disease.
• Recent treatment with amiodarone before the occurrence of POAF

Sponsors & Collaborators

• Ain Shams University: lead
• Misr International University: collaborator

Study Sites (1)

The Cardiovascular & Thoracic Academy - Ain Shams University.

Cairo, Egypt

Location

Related Publications (1)

• El Gindy DMK, Solayman MH, Khorshid R, Schaalan MF, El Wakeel LM. Effect of Clinical and Genetic Factors on the Development of Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting (CABG) in Egyptian Patients Receiving Beta-Blockers. Cardiovasc Drugs Ther. 2024 Feb;38(1):99-108. doi: 10.1007/s10557-022-07380-6. Epub 2022 Sep 15.

  PMID: 36107363 DERIVED

MeSH Terms

Conditions

Atrial Fibrillation

Interventions

Adrenergic beta-Antagonists

Condition Hierarchy (Ancestors)

Arrhythmias, Cardiac; Heart Diseases; Cardiovascular Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Adrenergic Antagonists; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Pharmacologic Actions; Chemical Actions and Uses; Physiological Effects of Drugs

Study Officials

• Dina M El Gindy, MSC

  Misr Ineternational University

  PRINCIPAL INVESTIGATOR

• Lamiaa M ElWakeel, PhD

  Ain Shams University

  STUDY CHAIR

• Mona F Schaalan, PhD

  Misr International University

  STUDY DIRECTOR

• Ramy MR Khorshid, Md, PhD

  Ain Shams Uiversity

  STUDY DIRECTOR

• Mohamed H Solayman, PhD

  Ain Sham University

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Lecturer of Clinical Pharmacy

Study Record Dates

• First Submitted: March 11, 2019
• First Posted: March 12, 2019
• Study Start: March 11, 2019
• Primary Completion: December 7, 2020
• Study Completion: March 7, 2021
• Last Updated: November 9, 2021

Record last verified: 2021-11

Locations

EG (1)